20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Latigo Biotherapeutics, Inc. Common Stock (LTGO) operates in the BIOTECHNOLOGY industry and is headquartered in Thousand Oaks, United States with about 66 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, LTGO reported $0M in revenue and ($109M) in net income.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($97M) | ($110M) | ($63M) |
| Operating Margin % | — | — | — |
| Net Income | ($96M) | ($109M) | ($61M) |
| Net Margin % | — | — | — |
| EBITDA | — | — | — |
| Earnings Per Share (EPS) | — | $-1.81 | $-1.02 |
| Shares Outstanding (M) | 60M | 60M | 60M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($26M) | ($23M) | ($26M) | ($22M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($26M) | ($23M) | ($26M) | ($21M) |
| Net Margin % | — | — | — | — |
| EBITDA | — | — | — | — |
| Earnings Per Share (EPS) | $-0.43 | $-0.38 | — | — |
| Shares Outstanding (M) | 60M | 60M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($91M) | ($98M) | ($51M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($91M) | ($98M) | ($51M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($21M) | ($27M) | ($22M) | ($21M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($21M) | ($27M) | ($22M) | ($21M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $65M | $76M | $23M |
| Cash & Cash Equivalents | $55M | $69M | $18M |
| Total Liabilities | $341M | $307M | $152M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M |
| Total Shareholders' Equity | ($276M) | ($232M) | ($130M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LTGO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms